Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets
MedComm · 2025-07 · 6 (7)
DOI: 10.1002/mco2.70292 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 11.07.2025. Verfasst von Yutao Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery Peking University People's Hospital Beijing China. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 499 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Cancer‐associated fibroblasts (CAFs) are functionally diverse stromal regulators that orchestrate tumor progression, metastasis, and therapy resistance through dynamic crosstalk within the tumor microenvironment (TME). Recent advances in single‐cell multiomics and spatial transcriptomics have identified conserved CAF subtypes with distinct molecular signatures, spatial distributions, and context‐dependent roles, highlighting their dual capacity to promote immunosuppression or restrain tumor growth. However, therapeutic strategies struggle to reconcile this functional duality, hindering clinical translation. This review systematically categorizes CAF subtypes by origin, biomarkers, and TME‐specific functions, focusing on their roles in chemoresistance, maintenance of stemness, and formation of immunosuppressive niches. We evaluate emerging targeting approaches, including selective depletion of tumor‐promoting subsets (e.g., fibroblast activation protein+ CAFs), epigenetic reprogramming toward antitumor phenotypes, and inhibition of CXCL12/CXCR4 or transforming growth factor‐beta signaling pathways. Spatial multiomics‐driven combinatorial therapies, such as the synergistic use of CAFs and immune checkpoint inhibitors, are highlighted as strategies to overcome microenvironment‐driven resistance. By integrating CAF biology with translational advances, this work provides a roadmap for developing subtype‐specific biomarkers and precision stromal therapies, directly informing efforts to disrupt tumor‐stroma coevolution. Key concepts include spatial transcriptomics, stromal reprogramming, and tumor‐stroma coevolution, offering actionable insights for both mechanistic research and clinical innovation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery Peking University People's Hospital Beijing China.
- Thoracic Oncology Institute Peking University People's Hospital Beijing China.
- Research Unit of Intelligence Diagnosis and Treatment in Early Non-Small Cell Lung Cancer Chinese Academy of Medical Sciences 2021RU002 Peking University People's Hospital Beijing China.
- Peking University Health Science Center Beijing China.
- Department of Nuclear Medicine Peking University People's Hospital Beijing China.
- Key Laboratory of Molecular Imaging of Chinese Academy of Sciences Institute of Automation Chinese Academy of Sciences Beijing China.
ORCID-Profile: Yutao Li, Kezhong Chen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
- Chinese Academy of Medical Sciences
Zitieren
APA
Li, Y., Liu, Q., Jing, X., Wang, Y., Jia, X., Yang, X., & Chen, K. (2025). Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets. MedComm, 6(7). https://doi.org/10.1002/mco2.70292
Vancouver
Li Y, Liu Q, Jing X, Wang Y, Jia X, Yang X, et al. Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets. MedComm. 2025;6(7). doi:10.1002/mco2.70292
BibTeX
@article{Li2025,
author = {Li, Yutao and Liu, Qingyun and Jing, Xilin and Wang, Yuqi and Jia, Xiaohua and Yang, Xing and Chen, Kezhong},
title = {Cancer‐Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets},
journal = {MedComm},
year = {2025},
volume = {6},
number = {7},
doi = {10.1002/mco2.70292}
}
EUVIMED